- Home
- MANH vs EXEL Comparison
MANH vs EXEL Comparison
Compare MANH & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MANH
- EXEL
- Stock Information
- Founded
- MANH 1990
- EXEL 1994
- Country
- MANH United States
- EXEL United States
- Employees
- MANH N/A
- EXEL N/A
- Industry
- MANH Computer Software: Prepackaged Software
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MANH Technology
- EXEL Health Care
- Exchange
- MANH Nasdaq
- EXEL Nasdaq
- Market Cap
- MANH 13.0B
- EXEL 11.1B
- IPO Year
- MANH 1998
- EXEL 2000
- Fundamental
- Price
- MANH $176.50
- EXEL $42.90
- Analyst Decision
- MANH Buy
- EXEL Buy
- Analyst Count
- MANH 12
- EXEL 24
- Target Price
- MANH $221.73
- EXEL $44.73
- AVG Volume (30 Days)
- MANH 608.3K
- EXEL 2.8M
- Earning Date
- MANH 10-21-2025
- EXEL 11-04-2025
- Dividend Yield
- MANH N/A
- EXEL N/A
- EPS Growth
- MANH 0.28
- EXEL 53.55
- EPS
- MANH 3.52
- EXEL 2.38
- Revenue
- MANH $1,066,804,000.00
- EXEL $2,288,218,000.00
- Revenue This Year
- MANH $5.34
- EXEL $9.14
- Revenue Next Year
- MANH $6.65
- EXEL $12.51
- P/E Ratio
- MANH $50.16
- EXEL $18.15
- Revenue Growth
- MANH 4.10
- EXEL 9.93
- 52 Week Low
- MANH $140.81
- EXEL $31.90
- 52 Week High
- MANH $312.60
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- MANH 43.98
- EXEL 60.15
- Support Level
- MANH $167.25
- EXEL $41.65
- Resistance Level
- MANH $175.33
- EXEL $42.99
- Average True Range (ATR)
- MANH 5.12
- EXEL 1.25
- MACD
- MANH 0.74
- EXEL 0.07
- Stochastic Oscillator
- MANH 64.56
- EXEL 79.18
About MANH Manhattan Associates Inc.
Manhattan Associates provides software that helps users manage their supply chains, inventory, and omnichannel operations. Customers are generally retailers, wholesalers, manufacturers, and logistics providers. The company was founded in 1990 and serves more than 1,200 customers around the world.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.